Compare OXLC & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXLC | SDGR |
|---|---|---|
| Founded | 2010 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 852.0M | 850.5M |
| IPO Year | N/A | 2020 |
| Metric | OXLC | SDGR |
|---|---|---|
| Price | $10.39 | $12.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $6.00 | ★ $21.00 |
| AVG Volume (30 Days) | 930.9K | ★ 1.4M |
| Earning Date | 11-01-2023 | 05-05-2026 |
| Dividend Yield | ★ 18.86% | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ 1.20 | N/A |
| Revenue | $130,145,365.00 | ★ $255,869,000.00 |
| Revenue This Year | $136.15 | $0.76 |
| Revenue Next Year | $5.51 | $4.60 |
| P/E Ratio | $8.64 | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $3.18 | $10.95 |
| 52 Week High | $18.20 | $27.63 |
| Indicator | OXLC | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 63.93 | 54.08 |
| Support Level | $9.88 | $11.08 |
| Resistance Level | $15.34 | $13.33 |
| Average True Range (ATR) | 0.20 | 0.71 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 75.97 | 54.59 |
Oxford Lane Capital Corp is a non-diversified closed-end management investment company. The fund's investment objective is to maximize its portfolio's risk-adjusted total return over its investment horizon. Its current focus is to seek that return by investing in equity and junior tranches of CLO(collateralized loan obligation) vehicles, which are collateralized by a diverse portfolio of senior loans, and which generally have little to no exposure to real estate loans, mortgage loans or pools of consumer-based debt, such as credit card receivables or auto loans. Its investment plan also includes investing in warehouse facilities, which are financing structures intended to aggregate senior loans that may be used to form the basis of a CLO vehicle.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.